Prestige Consumer Healthcare Inc. (NYSE:PBH) Expected to Post Quarterly Sales of $261.29 MillionOctober 2, 2021 Off By administrator
Analysts forecast that Prestige Consumer Healthcare Inc. (NYSE:PBH) will announce $261.29 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Prestige Consumer Healthcare’s earnings, with the lowest sales estimate coming in at $260.20 million and the highest estimate coming in at $262.80 million. Prestige Consumer Healthcare posted sales of $237.42 million in the same quarter last year, which suggests a positive year over year growth rate of 10.1%. The firm is scheduled to announce its next earnings results on Thursday, November 4th.
According to Zacks, analysts expect that Prestige Consumer Healthcare will report full year sales of $1.05 billion for the current fiscal year. For the next financial year, analysts expect that the business will report sales of $1.08 billion, with estimates ranging from $1.07 billion to $1.10 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Prestige Consumer Healthcare.
Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, August 5th. The company reported $1.14 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.27. Prestige Consumer Healthcare had a return on equity of 13.25% and a net margin of 18.18%. The firm had revenue of $269.10 million during the quarter, compared to the consensus estimate of $232.41 million. During the same period in the previous year, the firm posted $0.86 EPS. The company’s quarterly revenue was up 17.3% compared to the same quarter last year.
Several equities research analysts have issued reports on the stock. Royal Bank of Canada boosted their price objective on shares of Prestige Consumer Healthcare from $107.00 to $123.00 and gave the stock a “sector perform” rating in a research note on Friday, August 6th. Zacks Investment Research lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating and set a $55.00 target price for the company. in a research report on Tuesday, July 13th. Finally, DA Davidson raised their target price on shares of Prestige Consumer Healthcare from $52.00 to $61.00 and gave the stock a “neutral” rating in a report on Friday, August 6th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $98.67.
Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of Prestige Consumer Healthcare by 36.0% in the first…